BioLineRx Ltd. (BLRX) stock
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx Ltd. saw revenue fall 95.9% to $1.18M over fiscal 2025. Free cash flow was -$8.10M. At the latest close the market valued the company at $4.87M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $4.87M
- P/E ratio
- –
- Price to sales
- 4.13
- Price to book
- 0.35
- Dividend yield
- –
- Free cash flow yield
- -166.18%
Fundamentals
- Revenue
- $1.18M
- EPS, diluted
- $0.00
- Free cash flow
- -$8.10M
- Book value per share
- $0.01
- Diluted shares
- 2.66B
Trading
- Previous close
- $1.15
- Open
- $1.19
- Day's range
- $1.11 – $1.29
- Volume
- 33,180
- Average volume (20 days)
- 10,351
- 52-week range
- $1.11 – $3.95
- RSI (14 days)
- 11.2
- Volatility (1 year)
- 61.6%
- Relative volume
- 2.18×
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | BLRX | S&P 500 | Difference | BLRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -44.3% | -4.0% | −40.2 pts | ||
| 3 months | -57.6% | -5.0% | −52.6 pts | ||
| Year to date | -59.6% | +8.2% | −67.8 pts | ||
| 1 year | -67.0% | +11.2% | −78.2 pts | ||
| 3 years | -98.3% | +68.5% | −166.8 pts | -74.5% | +19.0% |
| 5 years | -99.0% | +67.3% | −166.3 pts | -60.1% | +10.8% |
| 10 years | -99.8% | +291.6% | −391.5 pts | -47.3% | +14.6% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases BioLineRx filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About BioLineRx
Pharmaceutical Preparations
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases. Its first approved drug is APHEXDA (motixafortide), a peptide indicated in the United States for stem cell mobilization for autologous transplantation in multiple myeloma patients. Commercialization and development of APHEXDA are handled by partners, including Ayrmid Pharma globally outside Asia and Auspex Bioscience in Asia. In addition, the company develops motixafortide for pancreatic cancer and other solid tumors, and collaborates on the clinical development of GLIX1, an oral small molecule candidate targeting DNA damage response in glioblastoma and other malignancies.
Company profile, executives and historyBioLineRx stock: common questions
What is BioLineRx's stock price?
BLRX closed at $1.12 on Nov 17, 2026, down 2.61% on the day. Over the past 52 weeks it traded between $1.11 and $3.95.
What is BioLineRx's market cap?
BioLineRx was worth $4.87M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is BLRX's P/E ratio?
BioLineRx lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does BioLineRx make?
BioLineRx reported revenue of $1.18M for fiscal 2025, down 95.9% from a year earlier.
Does BioLineRx pay a dividend?
No. BioLineRx has not paid a cash dividend over the last twelve months.
How has BLRX stock performed over the past year?
Including dividends, BLRX returned -67.0% over the past year, against +11.2% for the S&P 500.
Who are BioLineRx's competitors?
Companies most similar to BioLineRx by business, industry and size include ERNA, RFL, XTLB, MNOV, XBIO.
See a number that looks wrong?